Patents by Inventor Nicholas Rossi

Nicholas Rossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240026051
    Abstract: Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 25, 2024
    Inventors: Nicholas A. A. Rossi, Anatoly Pinchuk, Karen Neder, James Ludtke, Laura Juckem
  • Patent number: 11739174
    Abstract: Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 29, 2023
    Assignee: Mirus Bio LLC
    Inventors: Nicholas A. A. Rossi, Anatoly Pinchuk, Karen Neder, James Ludtke, Laura Juckem
  • Publication number: 20220214469
    Abstract: Certain exemplary embodiments can provide a device comprising an upper housing, a lower housing, an electronics module, an electronics button, a side button, and a strip magnet. The strip magnet is coupled to the lower housing. The strip magnet is constructed to cause resistance to motion across a metal fastener. The resistance to motion is perceptible to a user of the device. The resistance is indicative of a location of the metal fastener and, thereby, allows the user of the device to locate the metal fastener if the electronics module fails to detect the metal fastener.
    Type: Application
    Filed: July 15, 2021
    Publication date: July 7, 2022
    Inventor: Nicholas Rossi
  • Publication number: 20220041778
    Abstract: Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Application
    Filed: February 21, 2020
    Publication date: February 10, 2022
    Inventor: Nicholas A. A. Rossi
  • Publication number: 20210269570
    Abstract: Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Application
    Filed: February 21, 2020
    Publication date: September 2, 2021
    Applicant: Mirus Bio LLC
    Inventor: Nicholas A. A. Rossi
  • Patent number: 10619162
    Abstract: Cationic cyclic amine containing polymers and copolymers as well as novel lipids have been designed and synthesized for efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: April 14, 2020
    Assignee: Mirus Bio LLC
    Inventor: Nicholas A. A. Rossi
  • Patent number: 9786954
    Abstract: The electrolyte includes one or more salts and a silane. The silane has a silicon linked to one or more first substituents that each include a poly(alkylene oxide) moiety or a cyclic carbonate moiety. The silane can be linked to four of the first substituents. Alternately, the silane can be linked to the one or more first substituents and one or more second substituents that each exclude both a poly(alkylene oxide) moiety and a cyclic carbonate moiety.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: October 10, 2017
    Inventors: Robert C. West, Khalil Amine, Zhengcheng Zhang, Qingzheng Wang, Nicholas A. A. Rossi, Sang Young Yoon, Hiroshi Nakahara
  • Patent number: 9677077
    Abstract: Cationic acrylamide copolymers have been designed and synthesized for highly efficient delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: Mirus Bio LLC
    Inventor: Nicholas A. A. Rossi
  • Patent number: 9474804
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 25, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Patent number: 9452221
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: September 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Darren H Wakefield, Nicholas Rossi, David B Rozema, Lauren Almeida, Anthony L Perillo-Nicholas
  • Publication number: 20150283256
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: June 22, 2015
    Publication date: October 8, 2015
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Patent number: 9089611
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 28, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H Wakefield, Nicholas A Rossi, Dan Sheik
  • Publication number: 20150110732
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 23, 2015
    Inventors: Darren H. Wakefield, Nicholas A. Rossi, Dan Sheik
  • Publication number: 20150104408
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: November 25, 2014
    Publication date: April 16, 2015
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, Nicholas A. Rossi, David B. Rozema, Lauren J. Almeida, Anthony L. Perillo-Nicholas
  • Patent number: 8933047
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 13, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas
  • Patent number: 8932572
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: January 13, 2015
    Assignee: Arrowhead Madison Inc.
    Inventors: Darren H. Wakefield, Nicholas Rossi, Dan Sheik
  • Publication number: 20140342244
    Abstract: The electrolyte includes one or more salts and a silane. The silane has a silicon linked to one or more first substituents that each include a poly(alkylene oxide) moiety or a cyclic carbonate moiety. The silane can be linked to four of the first substituents. Alternately, the silane can be linked to the one or more first substituents and one or more second substituents that each exclude both a poly(alkylene oxide) moiety and a cyclic carbonate moiety.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 20, 2014
    Inventors: Robert C. West, Khalil Amine, Zhengcheng Zhang, Qingzheng Wang, Nicholas A.A. Rossi, Sang Young Yoon, Hiroshi Nakahara
  • Patent number: 8765295
    Abstract: The electrolyte includes one or more salts and a silane. The silane has a silicon linked to one or more first substituents that each include a poly(alkylene oxide) moiety or a cyclic carbonate moiety. The silane can be linked to four of the first substituents. Alternately, the silane can be linked to the one or more first substituents and one or more second substituents that each exclude both a poly(alkylene oxide) moiety and a cyclic carbonate moiety.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: July 1, 2014
    Inventors: Robert C. West, Khalil Amine, Zhengcheng Zhang, Qingzheng Wang, Nicholas A. A. Rossi, Sang Young Yoon, Hiroshi Nakahara
  • Publication number: 20130317079
    Abstract: The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: August 23, 2012
    Publication date: November 28, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, David B. Rozema, Nicholas Rossi, Lauren Almeida, Anthony L. Perillo-Nicholas
  • Publication number: 20130121954
    Abstract: The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness.
    Type: Application
    Filed: August 23, 2012
    Publication date: May 16, 2013
    Applicant: ARROWHEAD MADISON INC.
    Inventors: Darren H. Wakefield, Nicholas A. Rossi, Dan Sheik